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etter to the Editorfﬁcacy  of  Entecavir  therapy  in elderly patients
ith chronic  hepatitis  B  infection
infection.ear Editor,
hronic infection with hepatitis B virus (CHB) affects as many
s  350–400 million people worldwide and 93 million people
n  China.1 Moreover, elderly patients with CHB are increasing.
ence,  the treatment of elderly patients with CHB is an impor-
ant  issue. However, to our knowledge, there is no report about
he  efﬁcacy of Entecavir (ETV) treatment on elderly patients
≥60  years) with CHB.
A  retrospective cohort study was  conducted between
ebruary 2006 and March 2008; 40 consecutive Chinese
atients aged ≥60 years were enrolled in this study at Zhen-
iang  No. 3 Hospital. We also selected 40 patients aged <60
ears  with CHB on ETV therapy at same time, who were
atched to the ≥60 age group with respect to sex, alanine
minotransferase (ALT), HBV-DNA level, HBV genotype, and
BeAg  status and duration of therapy. The study protocol was
pproved  by the ethics committees of the hospital. All patients
ere  treated with Entecavir at a dose of 0.5 mg/day peroral.
Table 1 shows the rates of normalization of ALT level and
on-detection of HBV-DNA, among patients aged ≥60 years
nd  <60 years after six months and three years on ETV ther-
py.  The rates of ALT normalization of and of non-detection of
BV-DNA  in the two groups were  similar (p > 0.05 for the two
omparisons). Thirteen aged ≥60 years and nine patients aged
ess than 60 years underwent long-term liver biopsy (median
ime:  23 months, range: 12–39 months). Histological improve-
ent  (over 2-point decrease in the Knodell necroinﬂammatory
Table 1 – Rates of ALT normalization and of non-detection of HB
n ALT normalization rates (%) 
6 months 12 months 24 months 36
Age ≥60 years 40  87.5 87.5 90 
Aged <60 years 40 85 87.5 85 score and no worsening of the Knodell ﬁbrosis score) were
76.9%  (10/13) versus 77.8% (7/9) and ﬁbrosis improvement (the
Ishak  ﬁbrosis score ≥1-point decrease) were  38.5% (5/13) ver-
sus  44.4%(4/9) in two groups, respectively (p > 0.05 for the two
comparisons).
The  cumulative emergence rates of ETV resistance in
patients  aged ≥60 years and in those <60 years were  0%
and  0% at one year, 2.5% and 0% at two years, and 2.5%
and  2.5% at three years, respectively. The emergence rates
of  ETV resistance in patients aged ≥60 years were  simi-
lar  to those of patients aged <60 years at all three time
intervals. The cumulative rates of breakthrough hepatitis
in  patients aged ≥60 and <60 years were  0% and 0% at
one  year, 2.5% and 0% at two years, and 2.5% and 2.5%
at  three years, respectively (not signiﬁcant). The muta-
tion  clusters were rtI169T + rtL180M + rtM204V + rtM250 V and
rtL180M  + rtT184G + rtS202I, and rtM204 V, respectively. After
emergence  of the HBV mutant, we added adefovir dipivoxil
(ADV)  to ongoing ETV therapy.
The  beneﬁts of ETV in patients with compensated HBV-
related  liver disease have been suggested by several groups.2–5
Our study is the ﬁrst to show long-term efﬁcacy of ETV
monotherapy in older patients. Our results suggest that
the  treatment with ETV is not only well tolerated but
also  effective in the elderly population with chronic HBVV-DNA in patients aged ≥60 years and <60 years.
HBV-DNA non-detection rates (%)
 months 6 months 12 months 24 months 36 months
87.5 82.5 87.5 87.5 92.5
82.5 80 90 85 90
Further  studies are needed to conﬁrm the efﬁcacy and
safety  of ETV among the elderly.
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